Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, however, application to other therapies is questioned.

This groundbreaking research, published in Molecular Psychiatry, found that an anti-inflammatory drug called infliximab may ...

The first new drug approved for 50 years to treat a rare condition that creates swollen tissue on the lungs has been ...

A new biologic drug has been given to a patient with pulmonary sarcoidosis for the first time. The drug, infliximab, was administered at the John Radcliffe Hospital, part of Oxford University ...

A new study from Emory University has identified a biological connection between inflammation and deficits in motivation in individuals with schizophrenia, offering new hope for treating symptoms that ...

The primary endpoint of comprehensive disease control was defined as a combination of clinical remission (CDAI under 150; ...

Scientists identify the complex interplay between immune dysfunction, genetics, environment and disease progression driving ...

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

Given the dramatic changes in GLP-1 and biologic treatments and their rapid adoption, real-world data illuminating patient feedback and prescriber rationale is essential.” — Chris Baker, Amplity CEO ...

Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a ...

TNF Indicates Likelihood of Patient Response to Costly IBD Treatment Before Initiation of Therapy SAN DIEGO, CA / ACCESS Newswire / April 29, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a ...